1201902-80-8 | 4-(Carboxymethyl)-2-((R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)-6-oxo-1,3,2-dioxaborinane-4-carboxylic acid

Packsize	Purity	Availability	Price	Discounted Price
1mg	99%	in stock	$8.00	$6.00
5mg	99%	in stock	$24.00	$17.00
10mg	99%	in stock	$41.00	$29.00
25mg	95%	in stock	$80.00	$56.00
100mg	99%	in stock	$121.00	$85.00

Description

• Catalog Number: AA34209
• Chemical Name: 4-(Carboxymethyl)-2-((R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)-6-oxo-1,3,2-dioxaborinane-4-carboxylic acid
• CAS Number: 1201902-80-8
• Molecular Formula: C20H23BCl2N2O9
• Molecular Weight: 517.1216
• MDL Number: MFCD18251437
• SMILES: CC(C[C@@H](B1OC(=O)CC(O1)(CC(=O)O)C(=O)O)NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)C

Computed Properties

• Complexity: 815
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 34
• Hydrogen Bond Acceptor Count: 9
• Hydrogen Bond Donor Count: 4
• Rotatable Bond Count: 10
• Undefined Atom Stereocenter Count: 1

Literature

• The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.

  Future oncology (London, England) 20150101

• Ixazomib for the treatment of multiple myeloma.

  Expert opinion on investigational drugs 20150101

• Linker for activation of T-cell family member2 (LAT2) a lipid raft adaptor protein for AKT signaling, is an early mediator of alkylphospholipid anti-leukemic activity.

  Molecular & cellular proteomics : MCP 20121201

• Next-generation proteasome blockers promise safer cancer therapy.

  Nature medicine 20120106

• Drugs: More shots on target.

  Nature 20111214

• Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20111201

• In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110815

• Chemical and biological evaluation of dipeptidyl boronic acid proteasome inhibitors for use in prodrugs and pro-soft drugs targeting solid tumors.

  Journal of medicinal chemistry 20110714

• Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.

  Cancer research 20100301